Journals / Okmeydanı Tıp Dergisi / 2018 / Cilt: 34 - Sayı: 2

Does Tumor Localization of Operated NSCLC Have an Effect on Relapse and Survival?

Opere Küçük Hücre Dışı Akciğer Kanserinde Tümör Lokalizasyonunun Relaps ve Sağkalım Üzerine Etkisi Varmıdır?

Pages
71–75
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall survivaland relapse-free survival rates were compared accordingto the lobes.Results: In total 182 patients were included.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Our aim was to investigate the effect of tumorlocalization on relapse and survival in early stage lungcancer.Material and Methods: In this multicentered, retrospectivestudy, 182 early stage non small cell lung cancer patientswere included between the years of 2012-2015.
📊
Key Findings & Data:Overall survivaland relapse-free survival rates were compared accordingto the lobes.Results: In total 182 patients were included.
💡
Conclusion & Impact:Nosignificant effect was detected on relapse-free survival(p=0.862) and overall survival in terms of tumor localization.(p=0.750).Conclusion: In patients with early stage NSCLC, there wasno significant difference in relapse-free survival and overallsurvival in terms of tumor localization.
🔬Design:Research Article
📍Scope:2012-2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Our aim was to investigate the effect of tumorlocalization on relapse and survival in early stage lungcancer.Material and Methods: In this multicentered, retrospectivestudy, 182 early stage non small cell lung cancer patientswere included between the years of 2012-2015. The localizationsof the primary tumor were determined as rightupper lobe, right middle lobe, right lower lobe, left upperlobe, left middle lobe and left lower lobe. Overall survivaland relapse-free survival rates were compared accordingto the lobes.Results: In total 182 patients were included. The medianage was 61 years. Median follow up time was 24.8 months.Of the patients, 38 (20.9%) were stage 1, 82 (45.1%) werestage 2 and 62 (34.1%) were stage 3A. According to tumorlocalization, 23 (12.6%) were right lower lobe tumors,13 (7.1%) were right middle lobe tumors, 61 (33.5%)were right upper lobe tumors, 27 (14.8%) were left lowerlobe tumors, 58 (31.9%) were left upper lobe tumors. Nosignificant effect was detected on relapse-free survival(p=0.862) and overall survival in terms of tumor localization.(p=0.750).Conclusion: In patients with early stage NSCLC, there wasno significant difference in relapse-free survival and overallsurvival in terms of tumor localization.

Özet

Amaç: Akciğer heterojen bir organdır bu yüzden erken evre akciğer kanserinde tümör lokalizasyonunun nükse ve sağkalıma etkisini araştırmak istedik. Gereç ve Yöntem: Çalışmaya retrospektif multisentrik olarak 2012-2015 tarihleri arasında 182 erken evre küçük hücre dışı akciğer kanserli hasta alındı. Primer tümörün sağ üst lob, sağ orta lob, sağ alt lob, sol üst lob ve sol alt loblardaki lokalizasyonları tespit edildi. Loblara göre relapssız sağkalım ve genel sağkalım oranları karşılaştırıldı. Bulgular: Toplam 182 hasta alındı. Median yaş 61 idi. Median takip süresi 24.8 ay idi. 38 (%20,9) evre 1, 82 (%45,1) evre 2, 62 (%34,1) evre 3A hasta vardı. Tümör lokalizasyonuna bakıldığında sağ alt lob 23 (%12,6), sağ orta lob 13 (%7,1), sağ üst lob 61 (%33,5), sol alt lob 27 (%14,8), sol üst lob 58 (%31,9) tümör vardı. Tümör lokalizasyonu relapssız sağ kalım (p=0,862) ve genel sağ kalım (p=0,750) açısından anlamlı bir farklılık göstermedi. Sonuç: Erken evre küçük hücre dışı akciğer kanserli hastalarda tümör lokalizasyonu relapssız sağkalım ve genel sağkalım açısından herhengi bir anlamlı farklılık göstermedi.

🔖

Cite This Article

GEREDELİ, Ç. (2022). Does Tumor Localization of Operated NSCLC Have an Effect on Relapse and Survival?. Okmeydanı Tıp Dergisi, Cilt: 34 - Sayı: 2, 71–75. https://ajindex.com/articles/584977

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer Journal International du Cancer 2015;136:E359-86
  2. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
  3. Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-smallcell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. International Journal of Radiation Oncology, Biology, Physics 2008;72:695- 701.
  4. Delaney C, Frank S, Huang RS. Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond. Chin J Cancer 2015;34:149-60.
  5. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Annals of thoracic and cardiovascular surgery: official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. 2009;15:4-9
  6. Whitson BA, Groth SS, Andrade RS et al. T1/T2 nonsmall- cell lung cancer treated by lobectomy: does tumor anatomic location matter? The Journal of Surgical Research 2012;177:185-90.
  7. Puri V, Garg N, Engelhardt EE, et al. Tumor location is not an independent prognostic factor in early stage nonsmall cell lung cancer. The Annals of Thoracic Surgery 2010;89:1053-9.
  8. Iwasaki A, Shirakusa T, Enatsu S, et al. Is T2 non-small cell lung cancer located in left lower lobe appropriate to upstage? Interactive Cardiovascular and Thoracic Surgery 2005;4:126-9.
  9. Rocha AT, McCormack M, Montana G,et al. Association between lower lobe location and upstaging for earlystage non-small cell lung cancer. Chest 2004;125:1424- 30.
  10. Ou SH, Zell JA, Ziogas A, et al. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,70